文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

氯离子升高与危重患者主要不良肾脏事件相关

INCREASE IN CHLORIDE IS ASSOCIATED WITH MAJOR ADVERSE KIDNEY EVENTS IN CRITICALLY ILL PATIENTS.
PubMed 文献 · Shock · 2022-12-02
一句话结论ICU入科48小时内血氯升高≥5 mmol/L与30天主要不良肾脏事件(MAKE30)独立相关,而入科时高氯血症与之无关。

该回顾性研究纳入中国一家三级学术医院ICU于2020年4月至2022年4月收治的2024例成年患者,按入科血氯(高氯血症≥110 mmol/L vs 非高氯血症<110 mmol/L)及入科后48小时血氯升高幅度(ΔCl≥5 mmol/L vs <5 mmol/L)分组,主要终点为MAKE30(院内死亡、新接受肾脏替代治疗、持续性肾功能障碍)。结果显示高氯血症发生率为30.9%(n=625),ΔCl≥5 mmol/L发生率为18.5%(n=375),MAKE30总发生率为33.6%(n=680)。校正混杂因素后,ΔCl≥5 mmol/L与MAKE30发生率升高相关(OR 1.46;95%CI 1.096-1.93;P=0.010),而入科高氯血症与之无关(OR 0.99;95%CI 0.77-1.28;P=0.947)。作者认为ICU入科后48小时内血氯升高是MAKE30的独立危险因素,需大规模前瞻性研究验证。

要点

  • ICU入科后48小时内血氯升高≥5 mmol/L与MAKE30发生率升高独立相关(OR 1.46;95%CI 1.096-1.93;P=0.010)。
  • 入科时高氯血症(≥110 mmol/L)与MAKE30发生率无关(OR 0.99;95%CI 0.77-1.28;P=0.947)。
  • 研究人群MAKE30总发生率为33.6%(n=680),其中30天院内死亡率10.9%(n=220)、持续性肾功能障碍20.2%(n=408)、新接受RRT 18.0%(n=365)。
  • 高氯血症发生率为30.9%(n=625),ΔCl≥5 mmol/L发生率为18.5%(n=375)。
  • 作者认为ICU入科后48小时内血氯升高是MAKE30的独立危险因素,需大规模前瞻性研究验证。

适用人群与场景

  • 中国一家三级学术医院ICU于2020年4月至2022年4月收治的成年患者,共2024例,中位年龄67岁(IQR 55-76岁),中位APACHE II评分22分(IQR 17-28)。

诊断标准与关键阈值

  • 高氯血症定义为入ICU时血氯≥110 mmol/L,非高氯血症为<110 mmol/L。
  • 血氯升高幅度分组:ΔCl≥5 mmol/L与ΔCl<5 mmol/L(入ICU后48小时)。
  • MAKE30包括院内死亡、新接受肾脏替代治疗(RRT)和持续性肾功能障碍(PRD)。

研究设计与关键结果

  • 回顾性研究纳入2024例成年ICU患者,高氯血症发生率为30.9%(n=625),ΔCl≥5 mmol/L发生率为18.5%(n=375)。
  • MAKE30总发生率为33.6%(n=680),其中30天院内死亡率10.9%(n=220),总院内死亡率11.8%(n=238),持续性肾功能障碍20.2%(n=408),新接受RRT 18.0%(n=365)。
  • 校正混杂因素后,ΔCl≥5 mmol/L与MAKE30发生率升高相关(OR 1.46;95%CI 1.096-1.93;P=0.010)。
  • 校正混杂因素后,入科高氯血症与MAKE30发生率无关(OR 0.99;95%CI 0.77-1.28;P=0.947)。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。原文结论指出需大规模前瞻性研究验证。

对床旁实践的改变

  • 作者认为ICU入科后48小时内血氯升高是MAKE30的独立危险因素,需大规模前瞻性研究验证。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Purpose: This study aimed to identify the association between hyperchloremia at intensive care unit (ICU) admission and/or the increase of blood chloride levels and the incidence of major adverse kidney events within 30 days (MAKE30) in critically ill adults. Methods: We conducted a retrospective study to analyze the data of all adult patients admitted to the ICU of a tertiary academic hospital in China between April 2020 and April 2022. Patients were categorized based on their admission chloride levels (hyperchloremia ≥110 mmol/L and nonhyperchloremia <110 mmol/L) and stratified on the increased chloride levels 48 h after ICU admission (∆Cl ≥5 mmol/L and ∆Cl <5 mmol/L). The primary outcome was the MAKE30 incidence, including in-hospital death, new receipt of renal replacement therapy (RRT), and persistent renal dysfunction (PRD). Association between hyperchloremia at ICU admission and/or the increase of chloride and the incidence of MAKE30 were assessed using logistic regression. Result: A total of 2,024 patients with a median age of 67 years (interquartile range [IQR], 55-76 years) and a median Acute Physiology and Chronic Health Evaluation II score of 22 (IQR, 17-28) were included. Hyperchloremia occurred in 30.9% (n = 625), and ΔCl ≥5 mmol/L occurred in 18.5% (n = 375) of all ICU patients. The overall MAKE30 incidence was 33.6% (n = 680), including a 10.9% of 30-day hospital mortality (n = 220; as well as overall in-hospital mortality, 11.8% [n = 238]), a 20.2% (n = 408) of PRD, and a 18.0% (n = 365) of new RRT. After adjusted for confounders, it was found that ΔCl ≥5 mmol/L (odds ratio [OR], 1.46; 95% confidence interval [CI], 1.096-1.93; P = 0.010), but not hyperchloremia (OR, 0.99; 95% CI, 0.77-1.28; P = 0.947), was associated with increased incidence of MAKE30. Conclusion: An increased chloride level in the first 48 h of ICU admission was an independent risk factor for MAKE30, whereas hyperchloremia at ICU admission was not associated with an increased incidence of MAKE30. Large-scale prospective studies are needed to verify our findings.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Zhou D, Jiang J, Zhang J, et al. INCREASE IN CHLORIDE IS ASSOCIATED WITH MAJOR ADVERSE KIDNEY EVENTS IN CRITICALLY ILL PATIENTS. Shock. 2022. PMID: 36455261. doi:10.1097/SHK.0000000000002062

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。